	А	В	С
	Brand-Name Drug	Active ingredient	AG?
1	with Putative AG		(Yes/No)

	А	В	С	D	Е	F
	Brand-Name of Drug Subject to ¶ 4	Active Ingredient	Dosage Form	NDA#	Dosage Strength	AG? (Yes/No)
1						

	А	В	С	D	Е	F	G	Н	I	J
	AG Trade	Brand-Name	Active Ingredient	Dosage	NDA#	Dosage	NDA Date	AG - 9 digit	NDC Date	NDC Date of
	Name, if			Form		Strength	of	NDC #	of	Discontinuance, if
	any						Approval	(Labeler	Launch	any
							(for each	Code -		
							strength)	Product		
1								Code)		

	Н	K	L	M	N	0	Р	Q
	AG - 9 digit	AG Labeler/Entity	AG	AG Labeler/	QUESTION 7	STOP!!	QUESTION 10	QUESTION 11
	NDC #	Name	Labeler/Entity	Marketing	Coordinate	FILL IN	Date of first	Settlement
	(Labeler		Relationship to	Entity Address	with	COLUMNS P	announcement	agreement
	Code -		Company	& Phone	marketing	& Q WITH	of AG marketing	related to AG
	Product				entity?	PART III.		marketing?
1	Code)				(Yes/No)			(Yes/No)

	А	В	С	D	Е	F	G	Н		J
	Brand-Name (AG	Active	Dosage	NDA#	Dosage	NDA	9 digit	Labeler/Entity Name	Labeler/Entity	Therapeutic
	version marketed)	Ingredient	Form		Strength	Approval	NDC #		Relationship to	Category
						Date (for	(Labeler		Company	
						each	Code -			
						strength)	Product			
1							Code)			

	Α	K	L	М	N	0	Р	Q	R
	Brand-Name (AG	Pharmacological	14-Digit Generic	Date of	Generic	Name of ANDA-	Name of ANDA	Name of	Enter columns
	version marketed)	Class	Product Identifier	first	entry via 180	Generic	Generic	ANDA-	for additional
				ANDA-	day	Company #1	Company #2	Generic	companies
				generic	exclusivity?	During	During	Company #3	here▶▶
				entry (or	(Yes/No)	Exclusivity	Exclusivity	During	
1				"none")		•	_	Exclusivity	

	А	В	С	D	Е	F	G	Н	
1	Brand-Name (¶ IV- no AG marketed)	Active Ingredient	Dosage Form	NDA #	Dosage Strength	NDA Approval Date (for each strength)	9 digit NDC # (Labeler Code - Product Code)	Labeler/Entity Name	Labeler/Entity Relationship to Company

	Α	J	K	L	М	N	0	Р	Q	R	S
	Brand-Name (¶ IV-	Therapeutic	Pharma-	14-Digit	Date of	Generic	Name of	Name of	Name of	Enter	Question 14
	no AG marketed)	Category	cological	Generic	first	entry via 180	ANDA-	ANDA-	ANDA-	columns for	AG <u>NOT</u>
			Class	Product	ANDA-	day	Generic	Generic	Generic	additional	Marketed Per
				Identifier	generic	exclusivity?	Company #1	Company	Company	companies	Settlement
					entry (or	(Yes/No)	During	#2 During	#3 During	here▶▶	Agreement
					"none")		Exclusivity	Exclusivity	Exclusivity		(Yes/NO)
1								-			